Upcoming Presentations on Global Market Access Issues and Trends in Health Economics and Outcomes Research at ISPOR 2012 by Novel Health Strategies

Novel Health Strategies, LLC selected for multiple presentations on global market access and HEOR trends at ISPOR 2012. Studies highlight emerging trends and strategies for developing HEOR evidence

BETHESDA, Md., May 8, 2012 /PRNewswire-iReach/ -- Reimbursement strategy has become an integral component of drug and device development and commercialization plan. For new product launches it is becoming critical to demonstrate clinical, safety, economic and quality of life benefits versus comparators to payers, providers and patients. Novel Health Strategies, LLC's presentations at ISPOR 2012 highlight these trends: 

IMPACT OF 2009-2011 GLOBAL HEALTH CARE REFORMS ON PRICING, ACCESS AND HEALTH OUTCOMES STRATEGY (UT2, Tuesday, June 5, 2012, Podium Presentation)

COST EFFECTIVENESS TRENDS OF HIGH BUDGET IMPACT DRUGS (2006-2012) (CE1, Monday, June 4, 2012, Podium Presentation)

DEVELOPING BUDGET IMPACT MODEL FOR RARE DISEASES: CASE IN POINT CUTANEOUS T-CELL LYMPHOMA (PCN30, Wednesday, June 6, 2012)

ELECTRONIC PATIENT REPORTED OUTCOMES AND DATA TOOL FOR CHRONIC DISEASE MANAGEMENT (PROCDIM): CASE IN POINT PROSTATE CANCER (PIH32, Tuesday, June 5, 2012)

ONCOLOGY DRUG PRICES IN THE UNITED STATES AND THE UNITED KINGDOM: IMPLICATIONS FOR PRICING STRATEGY AND DRUG ACCESS (PCN116, Wednesday, June 6, 2012)

SYSTEMATIC REVIEW OF CLINICAL EFFICACY AND SAFETY OUTCOMES OF ANTI-VEGF THERAPIES FOR METASTATIC COLORECTAL CANCER (PCN114, Wednesday, June 6, 2012)

SYSTEMATIC REVIEW OF INTERFERON FREE BASED REGIMENS FOR CHRONIC HEPATITIS C TREATMENT (PIN5, Wednesday, June 6, 2012)

TRENDS IN RATE AND COST OF HOSPITALIZATIONS DUE TO CHRONIC KIDNEY DISEASE (CKD) IN THE UNITED STATES (PUK13, Tuesday, June 5, 2012)

Relevant References:

*Targeted Cancer Therapies, Nature Reviews Drug Discovery 9, 427-428 (June 2010)
http://novelhealthstrategies.com/Targeted_Cancer_Therapies.pdf
*What's Fueling the Biotech Engine-2010 to 2011, Nature Biotechnology 29, 1083–1089 (2011)
http://www.nature.com/nbt/journal/v29/n12/abs/nbt.2060.html
*Impact of 2009-2011 Global Healthcare Reforms on Access, Pricing and Health Outcomes Strategy, June 2, 2012
http://www.ispor.org/meetings/washingtondc0512/Program_060512.asp#podiums3

About Novel Health Strategies
Novel Health Strategies, LLC (http://www.novelhealthstrategies.com) is an award winning team of experienced professionals with expertise in healthcare strategy, research, policy, publications, health economics and outcomes research, modeling, and pricing and market access strategy. Novel Health team has led strategy projects for majority of top 50 pharmaceutical, biotech and device companies. Novel Health has large network of internal and external stakeholders and has published several thought leading strategy perspectives, including the 'What's fueling the biotech engine' annual series in Nature Biotech, cited and quoted by more than two hundred peer-reviewed publications and agencies (FDA, EMA and others). Novel Health has presented industry trends and perspectives at ISPOR, AMCP and BIO meetings. To learn more about Novel Health team's experience, case studies and capabilities, contact at the address on this press release.

Media Contact: Saurabh Aggarwal, PhD Novel Health Strategies, LLC, (202) 618-9365, info@novelhealthstrategies.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Novel Health Strategies, LLC



2017

Tags

Biotechnology, Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Pharmaceuticals, Trade Show News


Need Help